ANTIBIOTIC-RESISTANCE OF MICROBIAL FLORA ISOLATED FROM BIOPTATES MATERIAL FROM PATIENTS WITH ATHEROSCLEROSIS

The sensitivity of strains of microorganisms isolated from bioptates of atherosclerotic plaques to different antimicrobials was studied. For this study, the samples of atherosclerotic plaques from a group of patients that underwent elective carotid endarterectomy were used. Among 137 strains of coagulase-negative staphylococci 13.1 % of all isolates were methicillin-resistant, but all were sensitive to vancomycin, linezolid and moxifloxacin. Some strains of staphylococci possessed the resistance to erythromycin and tetracycline (16.3 %) and (13.9 %) respectively. The greatest resistance among coagulase-negative staphylococci to chloramphenicol (43.4 %) were identified. The high sensitivity of such bacteria to clindamycin, ciprofloxacin and gentamycin (92.6, 92.0 and 90.5 % respectively) were established. Among 197 isolates of Propionibacterium acnes all strains were highly sensitive to all antibiotics (amoxicillin, amoxicillin-clavulanic acid, benzylpenicillin, imipenem, clindamycin, piperacyllin, piperacyllin/tazobactam, ticarcillin, ticarcillin-clavulanic acid, chloramphenicol amd cefoxitin) which were tested. As exception was a metronidazole resistance to which bacteria are naturally refractory. The data obtained confirm that only small part of coagulase-negative staphylococci possessed the resistance to methicillin (13.1 %), but many among them demonstrated a high level of resistance to chloramphenicol. Between the strains of propionibacteria the acquired resistance to different antibacterials was not revealed.

atherosclerotic plaques, coagulase-negative staphylococci, propionibacterium, antibiotics sensitivity

1. Libby P. Inflammation in atherosclerosis. // Arterioscler.

2. Thromb. Vasc. Biol. 2012. Vol. 32, N 9. Р. 2045-2051.

3. Sessa R., Pietro M.D., Filardo S., Turriziani O. Infectious burden and atherosclerosis: a clinical issue // World. J. Clin. Cases. 2014. Vol. 2, N 7. P. 240-249.

4. Budzyсski J., Wiњniewska J., Ciecierski M., Kкdzia A. // Association between bacterial infection and peripheral vascular disease: a review // Int. J. Angiol. 2016. Mar. Vol. 25, N 1. P. 3-13.

5. Dietrich T., Sharma P., Walter C., Weston P., Beck J. // The epidemiological evidence behind the association between periodontitis and incident atherosclerotic cardiovascular disease // J. Periodontal. 2013. Vol. 84, N 4. Suppl. P. 70-84.

6. Шарифуллина Д.М., Васильева Р.М., Яковлева Т.И., Николаева Е.Г., Поздеев О.К., Ложкин А.П., Хайруллин Р.Н. Микробный пейзаж биоптатов атеросклеротических бляшек // Казанский мед. журн. 2015. Т. 96, № 6. С. 979-982.

7. Ziganshina E.E., Sharifullina D.M., Lozhkin A.P., Khayrullin R.N. et al. Bacterial communities associated with atherosclerotic plaques from russian individuals with atherosclerosis // PLoS One. 2016. Vol. 11, N 10. P. e0164836.

8. Muhlestein J.B., Anderson J.L., Carlquist J.F. et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study // Circulation. 2000. Vol. 102. P. 1755-1760.

9. O’Connor C.M., Dunne M.W., Pfeffer M.A. al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial // JAMA. 2003. Vol. 290. P. 1459-1466.

10. Gurfinkel E., Bozovich G., Daroca A., Beck E. et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study // ROXIS Study Group. Lancet. 1997. Vol. 350. P. 404-407.

11. Stone A.F., Mendall M., Kaski J.C., Gupta S. et al. Antibiotics against Chlamydia pneumonia and Helicobacter pylori reduce further cardiovascular events in patients with acute coronary syndromes [abstract] // J. Am. Coll. Cardiol. 2001.Vol. 37 (2 Suppl A) 349A.

12. Zahn R., Schneider S., Frilling B., Seidl K. et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study // Circulation. 2003. Vol. 107. P. 1253-1259.

13. Sinisalo J., Mattila K., Valtonen V., Anttonen O. et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome // Circulation. 2002. Vol. 105. P. 1555-1560.

14. Dunne M. WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics // Am. Heart J. 1999. Vol. 138 (5 Pt 2). P. 542-544.

15. Koren O., Spor A., Felin J., Fak F. et al. Human oral, gut and plaque microbiota in patients with atherosclerosis // PNA Sci. USA. 2011. Vol. 108, N l. P. 4592-4598.

16. Rafferty B., Jӧnsson D., Kalachikov S., Demmer R.T. et al. Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions. // J. Intern. Med. 2011. Vol. 270, N 3. P. 273-280.

17. Olszewski W.L., Rutkowska J. Moscicka-Wesolowska M. et al. // Bacteria of leg atheromatous arteries responsible for inflammation // Vasa. 2016. Sep. Vol. 45, N 5. P. 379-385.